GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Staar Surgical Co (NAS:STAA) » Definitions » ROE %

Staar Surgical Co (Staar Surgical Co) ROE % : 8.12% (As of Dec. 2023)


View and export this data going back to 1983. Start your Free Trial

What is Staar Surgical Co ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Staar Surgical Co's annualized net income for the quarter that ended in Dec. 2023 was $31.0 Mil. Staar Surgical Co's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $382.3 Mil. Therefore, Staar Surgical Co's annualized ROE % for the quarter that ended in Dec. 2023 was 8.12%.

The historical rank and industry rank for Staar Surgical Co's ROE % or its related term are showing as below:

STAA' s ROE % Range Over the Past 10 Years
Min: -31.61   Med: 4.49   Max: 13.34
Current: 5.95

During the past 13 years, Staar Surgical Co's highest ROE % was 13.34%. The lowest was -31.61%. And the median was 4.49%.

STAA's ROE % is ranked better than
62.15% of 811 companies
in the Medical Devices & Instruments industry
Industry Median: 0.13 vs STAA: 5.95

Staar Surgical Co ROE % Historical Data

The historical data trend for Staar Surgical Co's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staar Surgical Co ROE % Chart

Staar Surgical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.61 3.31 12.07 13.34 5.91

Staar Surgical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.24 3.21 7.00 5.26 8.12

Competitive Comparison of Staar Surgical Co's ROE %

For the Medical Instruments & Supplies subindustry, Staar Surgical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Staar Surgical Co's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Staar Surgical Co's ROE % distribution charts can be found below:

* The bar in red indicates where Staar Surgical Co's ROE % falls into.



Staar Surgical Co ROE % Calculation

Staar Surgical Co's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=21.347/( (336.112+385.954)/ 2 )
=21.347/361.033
=5.91 %

Staar Surgical Co's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=31.024/( (378.595+385.954)/ 2 )
=31.024/382.2745
=8.12 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Staar Surgical Co  (NAS:STAA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=31.024/382.2745
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(31.024 / 305.092)*(305.092 / 480.1065)*(480.1065 / 382.2745)
=Net Margin %*Asset Turnover*Equity Multiplier
=10.17 %*0.6355*1.2559
=ROA %*Equity Multiplier
=6.46 %*1.2559
=8.12 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=31.024/382.2745
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (31.024 / 54.956) * (54.956 / 41.62) * (41.62 / 305.092) * (305.092 / 480.1065) * (480.1065 / 382.2745)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.5645 * 1.3204 * 13.64 % * 0.6355 * 1.2559
=8.12 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Staar Surgical Co ROE % Related Terms

Thank you for viewing the detailed overview of Staar Surgical Co's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Staar Surgical Co (Staar Surgical Co) Business Description

Traded in Other Exchanges
Address
25651 Atlantic Ocean Drive, Lake Forest, CA, USA, 92630
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also make lenses which are used in surgery that treats cataracts. The company offers products are ICLs used in refractive surgery and IOLs used in cataract surgery. The company generated sales are from the ophthalmic surgical product segment.
Executives
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Elizabeth Yeu Lin director 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Warren Foust officer: Chief Operating Officer 17 MAGNOLIA DRIVE, LADERA RANCH CA 92694
Magda Michna officer: Chief Clinical, Regulatory, C/O PRESBIA, 8845 IRVINE CENTER DRIVE, SUITE 100, IRVINE CA 92618
Keith Holliday officer: V.P., Research & Development 1911 WALKER AVENUE, MONROVIA CA 91016
Robert Studholme officer: Senior VP, Operations 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630
James E Francese officer: VP, Global Marketing 1911 WALKER AVE, MONROVIA CA 91016
Caren L Mason director 2523 PARK RIDGE DRIVE, ESCONDIDO CA 92025
Samuel J Gesten officer: VP, General Counsel 1911 WALKER AVENUE, MONROVIA CA 91016
Patrick F. Williams officer: Chief Financial Officer C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
Hans-martin Blickensdoerfer officer: VP, International Marketing 1911 WALKER AVENUE, MONROVIA CA 91016
Lou Silverman director
Graydon C. Hansen officer: Sr. VP, Global Operations 25651 ATLANTIC OCEAN DRIVE, LAKE FORST CA 92630
Jon K. Hayashida officer: VP, Global Clinical, Medical 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA 92630